Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Hepatocellular 6Breast Neoplasms 4Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Locally Advanced Gastric Cancer 2Colorectal Neoplasms 2Cervical Cancer Metastatic 2Triple Negative Breast Neoplasms 1Sarcoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Rare Tumour 1Non-squamous Non-small Cell Lung Cancer 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Laryngeal Neoplasms 1Esophageal Squamour Cell Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Biliary Tract Neoplasms 1Advanced Triple Negative Breast Cancer 1Advanced Pancreatic Cancer 1

Interventions

lenvatinib 1camrelizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Triple Negative Breast Cancer × camrelizumab × Clear all
NCT06849492 2025-02-27

SHIFT-001

Fudan University

Phase 2 Not yet recruiting
120 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡